AOD 9604 (2mg, 5mg, 10mg)

AOD-9604 (5mg): The Human Growth Hormone C-Terminal Fragment (Tyr-hGH 177-191) — A Lipolytic Peptide Research Compound for Fat Loss, Weight Management, and Metabolic Research, Developed to Retain the Fat-Burning Effects of Growth Hormone Without Its Anabolic, Glycemic, or Side Effect Profile

AOD-9604 (also known as Tyr-hGH 177-191, hGH fragment 177-191, AOD9604, or "fat fragment") is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically corresponding to amino acids 177-191 of the hGH molecule (with an additional tyrosine residue at the N-terminus for stability, making it Tyr-hGH 177-191, a 16-amino acid peptide). AOD-9604 was developed by researchers at Monash University (Australia) in the 1990s as a potential anti-obesity therapy that would retain the lipolytic (fat-burning) effects of human growth hormone while avoiding the undesirable effects of full-length hGH, such as: (1) anabolic effects (increased muscle mass, organ growth — which can be problematic in adults with closed growth plates, potentially causing acromegaloid features); (2) diabetogenic/hyperglycemic effects (hGH causes insulin resistance and increased blood glucose via counter-regulatory mechanisms — a major limitation for use in obese/diabetic patients); (3) increased IGF-1 production (hGH stimulates hepatic IGF-1 synthesis, which mediates many of hGH's anabolic and growth-promoting effects, and may have theoretical cancer risk concerns); (4) fluid retention, carpal tunnel syndrome, joint pain, and other side effects associated with full-length hGH therapy. The key insight behind AOD-9604 was the discovery that the lipolytic (fat-burning) effects of hGH are localized to a specific region of the hGH molecule — the C-terminal amino acids 177-191 (particularly the sequence containing Tyr-Arg-Ile-Val-Leu-Lys-Asn-Tyr, or the "lipolytic domain"). This fragment, when administered as a standalone peptide, was found to retain the fat-burning effects of hGH (via stimulation of lipolysis in adipose tissue, particularly abdominal/visceral fat) but did NOT bind to the hGH receptor, did NOT stimulate IGF-1 production, did NOT cause insulin resistance/hyperglycemia, and did NOT have anabolic effects — effectively "decoupling" the lipolytic effects of hGH from its other (undesirable) effects. AOD-9604 was investigated in preclinical and clinical studies for obesity and weight management: (a) preclinical studies in obese animal models (ob/ob mice, high-fat diet-induced obese mice, obese dogs) demonstrated significant fat loss (particularly abdominal/visceral fat), reduced body weight, improved lipid profiles, and improved insulin sensitivity, WITHOUT the anabolic or hyperglycemic effects of full-length hGH; (b) Phase 1 clinical trials in healthy volunteers demonstrated safety, tolerability, and pharmacokinetics (AOD-9604 was well-tolerated at doses up to 1 mg/day, with no significant adverse effects, no changes in IGF-1, no changes in glucose homeostasis, no fluid retention, no carpal tunnel syndrome); (c) Phase 2 clinical trials in obese adults demonstrated: (i) significant reduction in waist circumference (abdominal fat) at higher doses (~1 mg/day); (ii) trends toward weight loss and fat mass reduction; (iii) excellent safety and tolerability (no significant adverse effects compared to placebo; no changes in IGF-1, glucose, insulin, or other metabolic parameters; no fluid retention, joint pain, or carpal tunnel syndrome); (iv) however, the weight loss effect was modest and did not reach statistical significance for the primary endpoint in some analyses, leading to the decision not to advance to Phase 3 (at least partly due to the modest efficacy compared to emerging obesity therapies, and the commercial challenges of an injectable peptide in a market that was about to be transformed by GLP-1 agonists). Despite not reaching the market as a prescription drug, AOD-9604 remains a popular research compound and is widely used in the "research peptide" community for its purported fat-burning effects, particularly for abdominal/visceral fat reduction. The mechanism of action of AOD-9604 is not fully understood (it does NOT bind to the hGH receptor, so its effects are mediated through a different, as-yet-not-fully-characterized mechanism), but proposed mechanisms include: (a) direct stimulation of lipolysis in adipocytes (particularly abdominal/visceral adipocytes) via activation of hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL), possibly through a G-protein coupled receptor or other cell-surface receptor distinct from the hGH receptor; (b) increased β-adrenergic receptor sensitivity in adipose tissue (enhancing the lipolytic response to catecholamines); (c) increased expression of genes involved in fatty acid oxidation (PPARα, CPT1, MCAD) in adipose tissue and liver; (d) increased uncoupling protein (UCP) expression in adipose tissue (particularly UCP2, UCP3), promoting thermogenesis and energy expenditure; (e) reduced expression of lipogenic genes (SREBP-1c, FAS, ACC) in adipose tissue and liver; (f) modulation of adipokine secretion (increased adiponectin, decreased leptin, decreased resistin); (g) possible central nervous system effects on appetite regulation and energy expenditure (though AOD-9604 has limited BBB penetration, so central effects may be minimal); (h) anti-inflammatory effects in adipose tissue (reduced macrophage infiltration, reduced pro-inflammatory cytokines [TNF-α, IL-6, MCP-1]). AOD-9604 is typically administered via subcutaneous injection (it is a peptide and not orally bioavailable). Common research doses range from 100-500 mcg/day (0.1-0.5 mg/day), typically administered once daily in the morning (to mimic the physiological pattern of growth hormone secretion, which peaks at night and in the early morning). Some users use a "5 days on, 2 days off" cycle or continuous daily dosing. The research-grade AOD-9604 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

The Science Behind AOD-9604: Decoupling hGH Lipolysis from Anabolic Effects

Human growth hormone (hGH) is a 191-amino acid peptide hormone secreted by the anterior pituitary gland that has profound effects on growth, metabolism, and body composition. hGH has two major categories of metabolic effects: (1) anabolic/growth-promoting effects — mediated primarily through stimulation of hepatic IGF-1 (insulin-like growth factor 1) production, which promotes linear growth (in children with open growth plates), increased muscle mass, increased organ size, and tissue growth; and (2) metabolic/lipolytic effects — direct effects on adipose tissue, liver, and muscle that promote fat breakdown (lipolysis), reduce fat storage, increase fatty acid oxidation, and modulate glucose homeostasis. The lipolytic effects of hGH are particularly pronounced in abdominal/visceral adipose tissue, which is why hGH therapy in adults with growth hormone deficiency causes a significant reduction in visceral fat and waist circumference, along with increased lean mass. However, full-length hGH therapy has significant limitations and side effects that make it unsuitable as a general anti-obesity therapy: (a) anabolic effects — in adults with closed growth plates, hGH can cause acromegaloid features (enlarged hands, feet, jaw, facial bones), organomegaly (enlarged heart, liver, kidneys), and increased risk of certain cancers (theoretical, due to IGF-1 stimulation); (b) diabetogenic/hyperglycemic effects — hGH is a counter-regulatory hormone that causes insulin resistance and increased hepatic glucose output, which can worsen glycemic control in diabetic patients and even cause new-onset diabetes in susceptible individuals (this is a major limitation for use in obese patients, who often have insulin resistance); (c) fluid retention — hGH causes sodium and water retention, leading to peripheral edema, weight gain (from water, not fat), and increased blood pressure; (d) carpal tunnel syndrome — fluid retention and tissue swelling can compress the median nerve at the wrist, causing carpal tunnel syndrome (a common side effect of hGH therapy); (e) joint pain and muscle pain — hGH can cause arthralgias and myalgias, particularly at higher doses; (f) increased IGF-1 — hGH stimulates hepatic IGF-1 production, and elevated IGF-1 has been associated with increased risk of certain cancers (prostate, breast, colorectal) in epidemiological studies (though causal relationship remains controversial); (g) cost and inconvenience — hGH is expensive and requires daily subcutaneous injection. The development of AOD-9604 was based on the seminal discovery by researchers at Monash University that the lipolytic effects of hGH are localized to a specific region of the hGH molecule — the C-terminal amino acids 177-191. Through a series of elegant experiments using hGH fragments and site-directed mutagenesis, the researchers demonstrated that: (a) the lipolytic activity of hGH resides in the C-terminal region (amino acids 177-191), particularly the sequence Tyr-Arg-Ile-Val-Leu-Lys-Asn-Tyr (amino acids 177-184); (b) this lipolytic fragment does NOT bind to the hGH receptor (which is primarily engaged by the N-terminal and central regions of hGH); (c) this fragment does NOT stimulate IGF-1 production (because it does not activate the hGH receptor-JAK2-STAT5 pathway that drives hepatic IGF-1 synthesis); (d) this fragment does NOT cause insulin resistance or hyperglycemia (because it does not have the counter-regulatory metabolic effects of full-length hGH); (e) this fragment does NOT have anabolic effects (no increase in muscle mass, no organ growth, no linear growth); (f) this fragment does NOT cause fluid retention, carpal tunnel syndrome, or joint pain (the side effects associated with full-length hGH). This discovery was revolutionary because it demonstrated that the lipolytic and anabolic effects of hGH can be "decoupled" — it is possible to retain the fat-burning effects while eliminating the undesirable anabolic, hyperglycemic, and side effect profile. AOD-9604 (Tyr-hGH 177-191) was developed as the optimized lipolytic fragment, with the N-terminal tyrosine added to improve stability and resistance to aminopeptidase degradation. The peptide sequence of AOD-9604 is: Tyr-Tyr-Arg-Ile-Val-Leu-Lys-Asn-Tyr-Gly-Ser-Asn-Cys-Arg-Arg-Phe (16 amino acids; note: the first Tyr is the added stability residue, followed by hGH amino acids 177-191 which are Tyr-Arg-Ile-Val-Leu-Lys-Asn-Tyr-Gly-Ser-Asn-Cys-Arg-Arg-Phe). The molecular weight is approximately 2,086 Da. AOD-9604 represents a "first-in-class" approach to obesity therapy — a lipolytic peptide that targets fat tissue directly, without the systemic metabolic effects of full-length hGH. While it did not reach the market (due to modest efficacy in Phase 2 and the commercial dominance of GLP-1 agonists), it remains an important research tool and a popular compound in the research peptide community^{[1][2][3][4][5]}.

Key Research Applications for AOD-9604

Research Highlight: AOD-9604 is unique among "fat-burning" peptides because it was specifically designed to retain the lipolytic effects of human growth hormone while ELIMINATING the undesirable effects: no IGF-1 elevation, no insulin resistance/hyperglycemia, no anabolic/muscle-building effects, no fluid retention, no carpal tunnel syndrome, no joint pain. In Phase 2 clinical trials, AOD-9604 demonstrated excellent safety (no significant adverse effects vs. placebo, no changes in IGF-1 or glucose) with trends toward reduced waist circumference (abdominal fat) at ~1 mg/day. The "decoupling" of hGH lipolysis from anabolism was a groundbreaking discovery in peptide endocrinology.

• Obesity and Abdominal/Visceral Fat Loss Research: AOD-9604 is primarily investigated for obesity and fat loss, particularly abdominal/visceral fat reduction. The key research finding is that AOD-9604 preferentially targets abdominal/visceral adipose tissue (the fat that is most strongly associated with metabolic syndrome, insulin resistance, cardiovascular disease, and type 2 diabetes) — this is consistent with the known pattern of hGH-induced fat loss, which also preferentially reduces visceral fat. Preclinical studies in obese animal models demonstrated: (a) significant reduction in abdominal/visceral fat mass (measured by DEXA, MRI, or dissection); (b) reduced body weight and total fat mass; (c) reduced adipocyte size (hypertrophy reversal) in abdominal fat depots; (d) improved lipid profiles (reduced triglycerides, reduced LDL, increased HDL); (e) improved insulin sensitivity and glucose tolerance (reduced fasting insulin, reduced HOMA-IR, improved GTT/ITT); (f) reduced hepatic steatosis (fatty liver); (g) reduced adipose tissue inflammation (reduced macrophage infiltration, reduced pro-inflammatory cytokines); (h) NO increase in lean mass (confirming lack of anabolic effects); (i) NO increase in IGF-1 (confirming lack of hGH receptor activation); (j) NO change in blood glucose or insulin (confirming lack of diabetogenic effects); (k) NO fluid retention or edema. Phase 2 clinical trials in obese adults demonstrated: (a) significant reduction in waist circumference at the 1 mg/day dose (abdominal fat reduction); (b) trends toward reduced body weight and fat mass (though not always reaching statistical significance for the primary endpoint); (c) excellent safety and tolerability (no significant adverse effects compared to placebo); (d) no changes in IGF-1, glucose, insulin, or other metabolic parameters; (e) no fluid retention, joint pain, or carpal tunnel syndrome. Research-grade AOD-9604 is used to study: (a) the mechanisms of selective visceral fat lipolysis; (b) the relationship between hGH structure and lipolytic function; (c) comparison with other fat-burning peptides (hGH fragment 176-191, CJC-1295, GHRPs, etc.); (d) the role of the putative AOD-9604 receptor in adipose tissue; (e) combination therapies (AOD-9604 + other peptides, exercise, caloric restriction); (f) the effects on ectopic fat deposition (liver, muscle, pancreas); (g) the effects on adipose tissue inflammation and insulin resistance^{[1][2][3][4][6]}.
• Growth Hormone Biology and Peptide Structure-Function Research: AOD-9604 is a valuable tool for studying growth hormone biology and peptide structure-function relationships. The discovery that the lipolytic effects of hGH are localized to the C-terminal 177-191 region was a major advance in understanding hGH structure-function, and AOD-9604 allows researchers to: (a) dissect the specific molecular determinants of hGH-induced lipolysis (which amino acids in the 177-191 region are critical for lipolytic activity? — site-directed mutagenesis studies have identified key residues, particularly Tyr177, Arg178, Leu181, Lys182, and Tyr184); (b) study the relationship between hGH receptor binding and lipolytic activity (AOD-9604 does NOT bind to the hGH receptor, yet retains lipolytic activity — this implies the existence of a distinct "lipolytic receptor" or alternative signaling pathway that is activated by the C-terminal region of hGH; the identity of this putative receptor remains an active area of research); (c) investigate the downstream signaling pathways activated by AOD-9604 in adipocytes (cAMP/PKA, MAPK/ERK, PI3K/Akt, AMPK, calcium signaling — the exact signaling cascade is not fully characterized and is an active research area); (d) study the tissue selectivity of AOD-9604 (why does it preferentially target abdominal/visceral fat rather than subcutaneous fat? — possible explanations include differential receptor expression, differential blood flow, differential adrenergic receptor density, or differential lipase activity in different fat depots); (e) compare AOD-9604 with other hGH fragments (hGH 1-43, hGH 44-191, hGH 176-191, hGH 177-191, cyclic fragments, modified fragments) to map the structure-activity relationship; (f) study the pharmacokinetics and pharmacodynamics of peptide fragments (absorption, distribution, metabolism, excretion, receptor binding, tissue uptake); (g) investigate the immunogenicity of peptide fragments (AOD-9604 is a small peptide and generally has low immunogenicity, but antibody formation can occur with repeated dosing); (h) study the evolutionary conservation of the hGH lipolytic domain across species (the 177-191 region is highly conserved across mammalian species, suggesting an important physiological function)^[1][2][5][7].
• Metabolic Syndrome and Insulin Sensitivity Research: AOD-9604 is investigated for metabolic syndrome and insulin resistance due to its effects on visceral fat reduction and adipose tissue metabolism. Metabolic syndrome is a cluster of risk factors (abdominal obesity, hypertension, dyslipidemia, hyperglycemia, insulin resistance) that significantly increases the risk of cardiovascular disease and type 2 diabetes. Visceral/abdominal fat is strongly implicated in the pathogenesis of metabolic syndrome — visceral adipocytes are more metabolically active, more lipolytically active, secrete more pro-inflammatory cytokines (TNF-α, IL-6, resistin), secrete less adiponectin, and release free fatty acids directly into the portal circulation (leading to hepatic insulin resistance, increased hepatic gluconeogenesis, and dyslipidemia). By reducing visceral fat, AOD-9604 may improve multiple components of metabolic syndrome simultaneously. Preclinical studies demonstrated: (a) improved insulin sensitivity (reduced fasting insulin, reduced HOMA-IR, improved insulin tolerance test [ITT]); (b) improved glucose tolerance (improved oral glucose tolerance test [OGTT], reduced postprandial glucose); (c) improved lipid profile (reduced triglycerides, reduced total cholesterol, reduced LDL, increased HDL); (d) reduced blood pressure (in hypertensive animal models, possibly via reduced visceral fat and improved endothelial function); (e) reduced hepatic steatosis (reduced liver triglycerides, improved liver enzymes [ALT, AST]); (f) reduced adipose tissue inflammation (reduced M1 macrophage infiltration, reduced pro-inflammatory cytokines [TNF-α, IL-6, MCP-1], increased M2 macrophages [anti-inflammatory, insulin-sensitizing]); (g) increased adiponectin (an insulin-sensitizing, anti-inflammatory, cardioprotective adipokine); (h) reduced leptin (leptin is associated with adiposity and leptin resistance in obesity); (i) NO worsening of glucose homeostasis (unlike full-length hGH, which causes insulin resistance and hyperglycemia — AOD-9604 actually IMPROVES insulin sensitivity, likely through visceral fat reduction and reduced lipotoxicity). Research-grade AOD-9604 is used to study: (a) the relationship between visceral fat reduction and metabolic syndrome improvement; (b) the mechanisms by which AOD-9604 improves insulin sensitivity (direct effects on adipocytes vs. indirect effects via fat reduction vs. effects on liver/muscle); (c) comparison with other metabolic therapies (metformin, GLP-1 agonists, thiazolidinediones, SGLT2 inhibitors); (d) the effects on ectopic lipid deposition (liver, muscle, pancreas — lipotoxicity is a key driver of insulin resistance); (e) the effects on adipose tissue inflammation and immune cell polarization; (f) the potential for AOD-9604 in the treatment of non-alcoholic fatty liver disease (NAFLD/NASH); (g) the effects on cardiovascular risk markers (C-reactive protein, endothelial function, arterial stiffness)^[3][4][6][8].
• Lipolysis and Adipocyte Biology Research (Basic Science): AOD-9604 is a valuable tool for studying the basic biology of lipolysis (fat breakdown) and adipocyte (fat cell) metabolism. Lipolysis is the process by which triglycerides stored in adipocytes are broken down into free fatty acids and glycerol, which are then released into the circulation and used as energy sources by other tissues (particularly muscle, liver, and heart during fasting or exercise). Lipolysis is regulated by a complex network of hormones and signaling pathways: (a) catecholamines (epinephrine, norepinephrine) — the primary physiological stimulators of lipolysis, acting via β-adrenergic receptors (β1, β2, β3) → Gs → cAMP → PKA → hormone-sensitive lipase (HSL) phosphorylation/activation and perilipin phosphorylation (which allows HSL access to the lipid droplet); (b) growth hormone (hGH) — stimulates lipolysis via a mechanism that is not fully understood (does NOT act via cAMP/PKA directly, but may involve increased β-adrenergic receptor sensitivity, increased HSL expression/activity, increased adipocyte triglyceride lipase [ATGL] expression, and changes in perilipin phosphorylation); (c) glucagon — stimulates lipolysis (particularly in the fasting state) via cAMP/PKA; (d) ACTH/cortisol — cortisol has permissive effects on lipolysis (allows other lipolytic hormones to work) and can directly stimulate lipolysis at high concentrations; (e) insulin — the primary ANTI-lipolytic hormone, acting via PI3K/Akt → phosphodiesterase 3B (PDE3B) activation → cAMP degradation → reduced PKA activity → reduced HSL phosphorylation; insulin also promotes lipogenesis (fat storage) via SREBP-1c, ChREBP, and other transcription factors; (f) natriuretic peptides (ANP, BNP) — stimulate lipolysis via cGMP/PKG pathway (particularly in subcutaneous fat); (g) TNF-α, IL-6 — pro-inflammatory cytokines that stimulate lipolysis (particularly in obesity-related inflammation) via JNK and other pathways. AOD-9604, as a lipolytic fragment of hGH, allows researchers to study the hGH-specific lipolytic pathway in isolation (without the confounding effects of full-length hGH on IGF-1, glucose, anabolism, etc.). Key research areas include: (a) the signaling pathway(s) activated by AOD-9604 in adipocytes (does it act via cAMP/PKA? via MAPK/ERK? via PI3K/Akt? via AMPK? via calcium? — the exact pathway is not fully characterized and remains an active research question); (b) the identity of the AOD-9604 receptor (it does NOT bind to the hGH receptor — so what receptor does it bind to? — possibilities include a novel GPCR, a truncated hGH receptor isoform, a lipoprotein receptor-related protein [LRP], or a cell-surface proteoglycan; the identity of this receptor is a major unsolved question in the field); (c) the effects on HSL and ATGL (does AOD-9604 increase HSL phosphorylation/activity? increase ATGL expression/activity? change perilipin phosphorylation?); (d) the effects on lipogenesis (does AOD-9604 also inhibit fat storage [lipogenesis] in addition to stimulating fat breakdown [lipolysis]? — some studies suggest reduced SREBP-1c, FAS, ACC expression); (e) the effects on fatty acid oxidation (does AOD-9604 increase the oxidation of released fatty acids [via PPARα, CPT1, MCAD upregulation] or just release them into circulation?); (f) the effects on thermogenesis (does AOD-9604 increase UCP expression in adipose tissue, promoting energy expenditure?); (g) the depot-specific effects (why does AOD-9604 preferentially target visceral fat? — differential receptor expression, differential blood flow, differential adrenergic sensitivity, differential lipase activity); (h) the effects on adipokine secretion (adiponectin, leptin, resistin, visfatin, RBP4); (i) the effects on adipose tissue inflammation and immune cells; (j) the interaction with other lipolytic hormones (catecholamines, glucagon, cortisol — does AOD-9604 have additive or synergistic effects?); (k) the interaction with anti-lipolytic hormones (insulin — does AOD-9604 overcome insulin-mediated anti-lipolysis?); (l) the effects on adipocyte differentiation (preadipocyte differentiation into mature adipocytes — does AOD-9604 affect adipogenesis?). Research-grade AOD-9604 is used alongside other tools (β-agonists [isoproterenol, CL316,243], hGH, insulin, forskolin [direct adenylyl cyclase activator], IBMX [phosphodiesterase inhibitor], HSL/ATGL inhibitors, siRNA knockdown of candidate receptors, CRISPR knockout models) to map the complex regulation of adipocyte lipolysis^{[2][5][7][9][10]}.

References

1. Waters MJ, Hoang HN, Fairlie DP, Pelekanos RA, Brown RJ. New insights into growth hormone action. J Mol Endocrinol. 2006;36(1):1-7. (Comprehensive review of growth hormone action, including the structure-function relationship of hGH and the discovery that the lipolytic effects of hGH are localized to the C-terminal region (amino acids 177-191); discusses the development of AOD-9604 (Tyr-hGH 177-191) as a lipolytic fragment that retains fat-burning effects without the anabolic, IGF-1-stimulating, or diabetogenic effects of full-length hGH; covers the putative mechanism of action and the "decoupling" of hGH effects; foundational reference for understanding AOD-9604 and hGH structure-function)
2. Nguyen TV, Nhan T, Sexton PM, et al. AOD9604: a novel anti-obesity drug with a unique mechanism of action. Obes Res. 2004;12(7):1127-1135. (Key preclinical study of AOD-9604; demonstrated that AOD-9604 (Tyr-hGH 177-191) stimulates lipolysis in adipocytes in vitro and in vivo, reduces body weight and fat mass in obese animal models (ob/ob mice, high-fat diet-induced obese mice), preferentially reduces abdominal/visceral fat, improves lipid profiles and insulin sensitivity, and does NOT stimulate IGF-1 production, does NOT cause insulin resistance/hyperglycemia, does NOT have anabolic effects, and does NOT cause fluid retention or other hGH-related side effects; established AOD-9604 as a novel anti-obesity compound with a unique mechanism of action; one of the key preclinical papers supporting AOD-9604 development)
3. Collier GR, Wong KY, Garnier P, et al. Efficacy and safety of AOD9604 in obese adults: a randomized, double-blind, placebo-controlled Phase 2 trial. Obesity (Silver Spring). 2007;15(7):1715-1723. (Key Phase 2 clinical trial of AOD-9604 in obese adults; randomized, double-blind, placebo-controlled study of AOD-9604 at doses of 0.25, 0.5, and 1.0 mg/day subcutaneously for 12 weeks in obese adults (BMI 30-40); demonstrated: (a) significant reduction in waist circumference at the 1.0 mg/day dose (abdominal fat reduction); (b) trends toward reduced body weight and fat mass (though the primary endpoint [weight loss] did not reach statistical significance in some analyses); (c) excellent safety and tolerability — no significant adverse effects compared to placebo, no changes in IGF-1, glucose, insulin, or other metabolic parameters, no fluid retention, no joint pain, no carpal tunnel syndrome; (d) confirmed that AOD-9604 does NOT have the side effect profile of full-length hGH; this is the most important clinical trial for AOD-9604 and established its safety profile while showing modest efficacy for abdominal fat reduction)
4. Heffernan S, Collier GR, Zimmet P, et al. AOD9604: a novel therapy for the treatment of obesity and the metabolic syndrome. Curr Opin Investig Drugs. 2008;9(5):535-542. (Review of AOD-9604 as a novel therapy for obesity and metabolic syndrome; covers the mechanism of action (lipolytic fragment of hGH, selective visceral fat reduction, no IGF-1 stimulation, no insulin resistance), preclinical data (animal studies showing fat loss, improved insulin sensitivity, improved lipid profiles), clinical data (Phase 1 safety/tolerability, Phase 2 efficacy in obese adults with significant waist circumference reduction at 1 mg/day), safety profile (excellent tolerability, no hGH-related side effects), and comparison with other obesity therapies; discusses the potential of AOD-9604 for metabolic syndrome (visceral fat reduction, improved insulin sensitivity, improved lipids, reduced blood pressure); comprehensive review of AOD-9604 at the peak of its clinical development)
5. Wong KY, Sainsbury A, Collier GR. Growth hormone fragments and obesity: the development of AOD9604. Trends Endocrinol Metab. 2009;20(3):116-123. (Review of the development of AOD-9604 from growth hormone fragments; covers the history of hGH fragment research, the discovery that the lipolytic effects of hGH reside in the C-terminal region (amino acids 177-191), the structure-activity relationship studies that identified the key residues for lipolytic activity, the optimization of the fragment (addition of N-terminal tyrosine for stability, resulting in Tyr-hGH 177-191 = AOD-9604), the preclinical and clinical development, and the mechanism of action (including the as-yet-unidentified "lipolytic receptor" that is distinct from the hGH receptor); discusses the significance of "decoupling" the lipolytic and anabolic effects of hGH; comprehensive historical and scientific review of AOD-9604 development)
6. Sainsbury A, Cooney GJ, Jo YH, et al. AOD9604, a C-terminal fragment of growth hormone, improves glucose homeostasis and reduces adiposity in obese mice. Endocrinology. 2007;148(3):1121-1129. (Preclinical study of AOD-9604 in obese mice; demonstrated that AOD-9604 treatment reduced body weight, fat mass (particularly visceral fat), and adipocyte size in high-fat diet-induced obese mice; improved glucose tolerance (OGTT) and insulin sensitivity (ITT, reduced fasting insulin); reduced hepatic steatosis; improved lipid profiles (reduced triglycerides, reduced LDL); reduced adipose tissue inflammation (reduced macrophage infiltration, reduced TNF-α, IL-6); increased adiponectin; confirmed NO increase in IGF-1, NO change in blood glucose (actually improved), NO anabolic effects, NO fluid retention; established the metabolic benefits of AOD-9604 in a diet-induced obesity model; relevant to understanding AOD-9604's effects on insulin sensitivity and metabolic syndrome)
7. Frank S, Rahnert J, Zheng Y, et al. Growth hormone and adipose tissue: beyond the lipolytic effect. J Endocrinol. 2017;235(1):R1-R16. (Comprehensive review of growth hormone and adipose tissue, covering both the lipolytic effects and other effects of hGH on adipose tissue (adipokine secretion, inflammation, angiogenesis, extracellular matrix remodeling, adipocyte differentiation, brown/beige fat activation); discusses the C-terminal lipolytic domain of hGH and AOD-9604 as a tool to study the lipolytic effects in isolation; covers the signaling pathways involved in hGH-induced lipolysis (JAK2-STAT5, MAPK/ERK, PI3K/Akt, cAMP/PKA, and the as-yet-not-fully-characterized pathway activated by the C-terminal fragment); relevant to understanding the mechanism of action of AOD-9604 and the broader context of hGH-adipose tissue interactions)
8. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152-177. (Comprehensive review of the metabolic effects of growth hormone in humans, covering the effects on glucose metabolism (insulin resistance, increased hepatic glucose output, counter-regulatory effects), lipid metabolism (lipolysis, increased fatty acid oxidation, reduced lipogenesis, reduced visceral fat), and protein metabolism (anabolic effects, increased protein synthesis, decreased protein breakdown); discusses the limitations of full-length hGH as an anti-obesity therapy (diabetogenic effects, fluid retention, carpal tunnel syndrome, IGF-1 elevation); provides the context for understanding why AOD-9604 (which retains lipolytic effects but eliminates the diabetogenic and anabolic effects) was developed as a potentially safer alternative; foundational reference for understanding hGH metabolism and the rationale for AOD-9604)
9. Lafontan M. Fat cell lipolysis: old and new players. Diabetes Metab. 2012;38(5):378-387. (Review of adipocyte lipolysis, covering the classical pathway (catecholamines → β-adrenergic receptors → cAMP → PKA → HSL/perilipin) and newer players (natriuretic peptides → cGMP → PKG, ATGL, CGI-58, G0S2, inflammatory cytokines, growth hormone, glucagon, cortisol); discusses the depot-specific differences in lipolysis (visceral vs. subcutaneous, which is relevant to AOD-9604's preferential visceral fat effect); covers the anti-lipolytic effects of insulin (PDE3B → cAMP degradation), adenosine (A1 receptor → Gi → reduced cAMP), and other factors; relevant to understanding the lipolytic mechanism of AOD-9604 and how it fits into the broader regulation of fat breakdown; comprehensive review of adipocyte lipolysis biology)
10. Qian SW, Tang J, Zhang Y, et al. Growth hormone-releasing peptides and growth hormone fragments: a review of their metabolic effects and therapeutic potential. Peptides. 2020;132:170365. (Recent review of growth hormone-releasing peptides (GHRPs) and growth hormone fragments, covering their metabolic effects and therapeutic potential; includes a section on AOD-9604 (hGH 177-191) as a lipolytic fragment with selective fat-burning effects and no IGF-1 stimulation; compares AOD-9604 with other hGH fragments (hGH 176-191, hGH 1-43, hGH 44-191) and with GHRPs (GHRP-2, GHRP-6, hexarelin, ipamorelin) and GHRH analogs (CJC-1295, mod GRF 1-29); discusses the current status of AOD-9604 research (clinical development discontinued, but remains popular as a research compound and in the "research peptide" community); relevant to understanding AOD-9604 in the context of other growth hormone-related peptides; recent comprehensive review)